Xtant Medical Company Insiders
XTNT Stock | USD 0.40 0.01 2.44% |
Xtant Medical employs about 207 people. The company is managed by 6 executives with a total tenure of roughly 6 years, averaging almost 1.0 years of service per executive, having 34.5 employees per reported executive. Breaking down Xtant Medical's management performance can provide insight into the firm performance.
Kevin Brandt President Senior Vice President Chief Commercial Officer |
Xtant |
Xtant Medical Management Team Effectiveness
The company has return on total asset (ROA) of (0.1058) % which means that it has lost $0.1058 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0877) %, meaning that it created substantial loss on money invested by shareholders. Xtant Medical's management efficiency ratios could be used to measure how well Xtant Medical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Xtant Medical's Return On Tangible Assets are comparatively stable compared to the past year. Return On Assets is likely to gain to 0.01 in 2024, whereas Return On Capital Employed is likely to drop (0.15) in 2024. Change To Liabilities is likely to gain to about 1.9 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 16 M in 2024.Common Stock Shares Outstanding is likely to gain to about 133.1 M in 2024, whereas Net Loss is likely to drop (10.2 M) in 2024.
Xtant Medical Workforce Comparison
Xtant Medical Holdings is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 9,117. Xtant Medical holds roughly 207 in number of employees claiming about 2.27% of equities under Health Care industry.
Xtant Medical Profit Margins
The company has Profit Margin (PM) of (0.03) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.1) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.1.Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Gross Profit Margin | 0.49 | 0.6075 |
|
|
Xtant Medical Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Xtant Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Xtant Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Xtant Medical insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sean Browne over a month ago Disposition of 105442 shares by Sean Browne of Xtant Medical at 0.59 subject to Rule 16b-3 | ||
Sean Browne over three months ago Disposition of 10606 shares by Sean Browne of Xtant Medical at 0.6 subject to Rule 16b-3 | ||
Sean Browne over six months ago Disposition of 80000 shares by Sean Browne of Xtant Medical at 0.6751 subject to Rule 16b-3 | ||
Michael Eggenberg over six months ago Acquisition by Michael Eggenberg of 46784775 shares of Xtant Medical at 1.07 subject to Rule 16b-3 | ||
Sean Browne over six months ago Acquisition by Sean Browne of 731632 shares of Xtant Medical subject to Rule 16b-3 | ||
Scott Neils over six months ago Acquisition by Scott Neils of 177551 shares of Xtant Medical subject to Rule 16b-3 | ||
Vizirgianakis Stavros G over a year ago Acquisition by Vizirgianakis Stavros G of 217770 shares of Xtant Medical subject to Rule 16b-3 |
Xtant Medical Notable Stakeholders
A Xtant Medical stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xtant Medical often face trade-offs trying to please all of them. Xtant Medical's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xtant Medical's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sean Browne | CEO President | Profile | |
Kevin Brandt | Senior Vice President Chief Commercial Officer | Profile | |
Scott Neils | Chief Officer | Profile | |
Kevin ODare | VP US | Profile | |
Catherine Lundy | Vice Resources | Profile | |
Mark Schallenberger | Chief Officer | Profile |
About Xtant Medical Management Performance
The success or failure of an entity such as Xtant Medical Holdings often depends on how effective the management is. Xtant Medical management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xtant management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xtant management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | 0.01 | 0.01 | |
Return On Capital Employed | (0.15) | (0.15) | |
Return On Assets | 0.01 | 0.01 | |
Return On Equity | 0.01 | 0.01 |
Please note, the imprecision that can be found in Xtant Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xtant Medical Holdings. Check Xtant Medical's Beneish M Score to see the likelihood of Xtant Medical's management manipulating its earnings.
Xtant Medical Workforce Analysis
Traditionally, organizations such as Xtant Medical use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xtant Medical within its industry.Xtant Medical Manpower Efficiency
Return on Xtant Medical Manpower
Revenue Per Employee | 441.1K | |
Revenue Per Executive | 15.2M | |
Net Income Per Employee | 3.2K | |
Net Income Per Executive | 110K | |
Working Capital Per Employee | 202.3K | |
Working Capital Per Executive | 7M |
Additional Tools for Xtant Stock Analysis
When running Xtant Medical's price analysis, check to measure Xtant Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xtant Medical is operating at the current time. Most of Xtant Medical's value examination focuses on studying past and present price action to predict the probability of Xtant Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xtant Medical's price. Additionally, you may evaluate how the addition of Xtant Medical to your portfolios can decrease your overall portfolio volatility.